Which feature best distinguishes IBD from IBS?
Choose an answer, then check it.
Clinical Pharmacology · Nausea, Bowel, and Motility Medications
Irritable Bowel and Inflammatory Bowel Medications
On this page 6 sections
In 30 seconds
Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) share the letters and the neighborhood but are different diseases treated with different drug classes. IBS is a disorder of gut-brain signaling — the bowel looks structurally normal but behaves abnormally — so treatment targets symptoms like spasm, transit speed, and pain perception. IBD (Crohn disease and ulcerative colitis) is immune-mediated structural inflammation that can cause strictures, fistulas, and colorectal cancer, so treatment suppresses the underlying immune attack. Mixing up the two means reaching for the wrong pharmacologic strategy entirely.
The college version
IBS versus IBD: the core distinction
IBS is diagnosed by symptom pattern (recurrent abdominal pain with altered bowel habits) after structural disease is excluded; colonoscopy looks normal, and there is no tissue destruction, bleeding, or cancer risk beyond baseline. IBD is confirmed by visible mucosal inflammation, biopsy findings, and imaging; it carries real risk of bowel-wall scarring, abnormal tracts (fistulas), and malignant transformation over time. This distinction drives everything downstream: IBS drugs modulate motility, secretion, and visceral sensation; IBD drugs modulate the immune system itself.
IBS: symptom-directed therapy by subtype
Patients are classified as IBS-C (constipation-predominant), IBS-D (diarrhea-predominant), or mixed, and therapy follows the dominant symptom.
Antispasmodics such as dicyclomine and hyoscyamine are anticholinergics that relax intestinal smooth muscle to ease cramping pain, at the cost of typical anticholinergic effects (dry mouth, blurred vision, urinary retention). Peppermint oil works similarly by blocking calcium influx into gut smooth muscle and is a reasonable over-the-counter option. Soluble fiber helps regulate stool form in either direction and is often first-line.
For IBS-C: lubiprostone activates intestinal chloride channels, linaclotide and plecanatide activate guanylate cyclase-C to increase fluid secretion, and tegaserod, a 5-HT4 agonist that stimulates motility, carries cardiovascular risk history that restricts its use to appropriate candidates.
For IBS-D: loperamide, an opioid-receptor agonist, slows transit without central effects at typical use; rifaximin, a poorly absorbed antibiotic, modulates gut flora; eluxadoline, a mixed opioid agonist-antagonist, is avoided in patients without a gallbladder or with prior pancreatitis; and alosetron, a 5-HT3 antagonist, is available only through a restricted prescribing program because of ischemic colitis and severe constipation risk, reserved for women with severe, treatment-refractory IBS-D.
Low-dose tricyclic antidepressants and SSRIs reduce visceral hypersensitivity through central and peripheral neuromodulation, working at doses well below their antidepressant range. Dietary approaches (low-FODMAP elimination) and behavioral therapies (cognitive-behavioral therapy, gut-directed hypnotherapy) address the gut-brain axis directly and are core, not adjunctive, treatment.
IBD: the treatment ladder
Aminosalicylates like mesalamine act topically on the gut mucosa and are useful mainly in mild-to-moderate ulcerative colitis; sulfasalazine, an older prodrug, splits into an active moiety plus a sulfapyridine carrier that causes sulfa-allergy reactions and blocks folate absorption, requiring folate supplementation.
Corticosteroids, including budesonide, induce remission quickly but are not maintenance drugs — budesonide's high first-pass hepatic metabolism limits systemic steroid exposure somewhat, but chronic steroid side effects still make induction-only use the rule for the whole class. This underlies the steroid-sparing strategy: use steroids to bridge a flare while a slower-acting maintenance agent takes effect, then taper off.
Immunomodulators — azathioprine, 6-mercaptopurine, and methotrexate — maintain remission and spare steroids. Azathioprine and 6-mercaptopurine require TPMT (or NUDT15) enzyme testing before starting, since poor metabolizers risk severe bone marrow suppression.
Biologics target specific immune pathways. Anti-TNF agents (infliximab, adalimumab, certolizumab pegol, golimumab) require tuberculosis and hepatitis B screening before initiation, since suppressing TNF can reactivate latent infection; ongoing monitoring watches for infection and lymphoma risk. Vedolizumab, an anti-integrin, is gut-selective, blocking lymphocyte trafficking into intestinal tissue specifically and carrying a more favorable systemic infection profile. Ustekinumab and risankizumab target interleukin-12/23 and interleukin-23 pathways respectively. JAK inhibitors are oral options with their own boxed warnings for clotting and cardiovascular events, reserved for refractory disease.
Across the ladder: induction (rapid symptom control) and maintenance (sustained remission) require different agents; vaccinations should be updated before immunosuppression begins, since live vaccines become contraindicated once a patient is immunosuppressed; and lifelong monitoring for infection and malignancy is part of the therapy, not an afterthought.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Picture two different problems with a garden hose. IBS is like a hose that's perfectly fine but keeps kinking, spraying too fast, or barely dripping — nothing is broken, it just doesn't behave right, so you adjust the water pressure or gently uncoil it. IBD is like a hose with actual burned, cracked sections that are inflamed and could tear or leak permanently — you can't just adjust pressure, you have to calm down the "fire" damaging the hose itself. IBS medicines are like pressure and flow adjustors. IBD medicines are like firefighters that turn down the immune system's overreaction so the hose stops getting damaged. Doctors check the hose carefully first (colonoscopy, biopsies) to know which problem they're actually dealing with, because using a pressure adjustor on a burned hose won't put out the fire.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient with severe IBS-D has failed multiple therapies and is being considered for alosetron. What safety consideration must be addressed before and during treatment?
Show answer
Monitor for ischemic colitis and severe constipation
Alosetron can cause reduced blood flow to the colon and dangerous constipation, so it's only available through a restricted program with close monitoring and patient education on warning signs like worsening abdominal pain or bloody stools.
A patient is about to start infliximab for Crohn disease. What two screenings must be completed beforehand, and why do they matter?
Show answer
Screen for tuberculosis and hepatitis B before starting
Anti-TNF biologics suppress part of the immune system that normally keeps latent TB and hepatitis B in check, so screening catches these infections beforehand to prevent a dangerous reactivation once treatment begins.
Quick check
3 questions here. Answers stay hidden until you check.
Why must TPMT (or NUDT15) testing occur before starting azathioprine or 6-mercaptopurine?
Choose an answer, then check it.
What is the primary reason corticosteroids like budesonide are used for induction only, not maintenance, in IBD?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.